ACM
EW icon

Altium Capital Management’s Edwards Lifesciences EW Stock Holding History

Altium Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-165,000
Closed -$12.2M – 43
2024
Q4 		$12.2M Sell
165,000
-57,000
-26% -$3.99M 3.46% 8
2024
Q3 		$14.6M Buy
+222,000
New +$16.1M 4.31% 4

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Altium Capital Management's EW Position: Q1 2025 in Review

Altium Capital Management sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 165,000 shares — an estimated $12.2M sold.

Altium Capital Management first reported a position in EW in Q3 2024 and held it in 2 quarters. The position peaked at $14.6M in Q3 2024. 1,205 funds tracked by Wall St. Rank hold EW as of Q1 2025.

  • Altium Capital Management reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 165,000 Edwards Lifesciences shares in Q1 2025, an estimated $12.2M.
  • Altium Capital Management first reported a position in Edwards Lifesciences in Q3 2024 and held it in 2 quarters.
  • Altium Capital Management's Edwards Lifesciences position peaked at $14.6M in Q3 2024.
  • 1,205 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.